Literature DB >> 19942356

Carotid-sparing intensity-modulated radiotherapy for early-stage squamous cell carcinoma of the true vocal cord.

Bhishamjit S Chera1, Robert J Amdur, Christopher G Morris, William M Mendenhall.   

Abstract

PURPOSE: To compare radiation doses to carotid arteries among various radiotherapy techniques for treatment of early-stage squamous cell carcinoma (SCC) of the true vocal cords. METHODS AND MATERIALS: Five patients were simulated using computed tomography (CT). Clinical and planning target volumes (PTV) were created for bilateral and unilateral stage T1 vocal cord cancers. Planning risk volumes for the carotid arteries and spinal cord were delineated. For each patient, three treatment plans were designed for bilateral and unilateral target volumes: opposed laterals (LATS), three-dimensional conformal radiotherapy (3DCRT), and intensity-modulated radiotherapy (IMRT), for a total of 30 plans. More than 95% of the PTV received the prescription dose (63Gy at 2.25 Gy per treatment).
RESULTS: Carotid dose was lowest with IMRT. With a bilateral vocal cord target, the median carotid dose was 10Gy with IMRT vs. 25 Gy with 3DCRT and 38 Gy with LATS (p < 0.05); with a unilateral target, the median carotid dose was 4 Gy with IMRT vs. 19 Gy with 3DCRT and 39 Gy with LATS (p < 0.05). The dosimetric tradeoff with IMRT is a small area of high dose in the PTV. The worst heterogeneity results were at a maximum point dose of 80 Gy (127%) in a unilateral target that was close to the carotid.
CONCLUSIONS: There is no question that IMRT can reduce the dose to the carotid arteries in patients with early-stage vocal cord cancer. The question is whether the potential advantage of reducing the carotid dose outweighs the risk of tumor recurrence due to contouring errors and organ motion and the risk of complications from dose heterogeneity. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19942356     DOI: 10.1016/j.ijrobp.2009.07.1687

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  T1-2 glottic cancer treated with radiotherapy and/or surgery.

Authors:  Mohamed Shelan; Lukas Anschuetz; Adrian D Schubert; Beat Bojaxhiu; Alan Dal Pra; Frank Behrensmeier; Daniel M Aebersold; Roland Giger; Olgun Elicin
Journal:  Strahlenther Onkol       Date:  2017-05-04       Impact factor: 3.621

2.  Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation.

Authors:  Abdallah S R Mohamed; Blaine D Smith; Joshua B Smith; Parag Sevak; Jessica S Malek; Aasheesh Kanwar; Theodora Browne; G Brandon Gunn; Adam S Garden; Steven J Frank; William H Morrison; Jack Phan; Mark Zafereo; Heath Skinner; Stephen Y Lai; Katherine A Hutcheson; Jan S Lewin; Amy E Hessel; Apurva A Thekdi; Randal S Weber; Clifton D Fuller; David I Rosenthal
Journal:  Laryngoscope       Date:  2019-02-12       Impact factor: 3.325

3.  Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma.

Authors:  Zachary S Zumsteg; Nadeem Riaz; Sana Jaffery; Man Hu; Daphna Gelblum; Ying Zhou; Borys Mychalczak; Michael J Zelefsky; Suzanne Wolden; Shyam Rao; Nancy Y Lee
Journal:  Oral Oncol       Date:  2015-05-07       Impact factor: 5.337

4.  Risk of fatal cerebrovascular accidents after external beam radiation therapy for early-stage glottic laryngeal cancer.

Authors:  Samuel Swisher-McClure; Nandita Mitra; Alexander Lin; Peter Ahn; Fei Wan; Bert O'Malley; Gregory S Weinstein; Justin E Bekelman
Journal:  Head Neck       Date:  2013-07-02       Impact factor: 3.147

5.  Volumetric modulated arc radiotherapy of the whole larynx, followed by a single affected vocal cord, for T1a glottic cancer: Dosimetric analysis of a case.

Authors:  Seung-Gu Yeo
Journal:  Mol Clin Oncol       Date:  2016-01-14

6.  Outcomes after radiation therapy for T2N0/stage II glottic squamous cell carcinoma.

Authors:  Karine A Al Feghali; Bassem Y Youssef; Abdallah S R Mohamed; Lara Hilal; Blaine D Smith; Ibrahim Abu-Gheida; Georges Farha; G Brandon Gunn; Jack Phan; Jan Lewin; Apurva Thekdi; William H Morrison; Adam S Garden; Clifton David Fuller; David I Rosenthal
Journal:  Head Neck       Date:  2020-06-02       Impact factor: 3.147

7.  Carotid dosimetry for T1 glottic cancer radiotherapy.

Authors:  K Garcez; C C Lim; P Whitehurst; D Thomson; K F Ho; M Lowe; A Sykes; L W Lee; B Yap; N Slevin
Journal:  Br J Radiol       Date:  2014-02-17       Impact factor: 3.039

Review 8.  Standardisation of Target Volume Delineation for Carotid-sparing Intensity-modulated Radiotherapy in Early Glottis Cancer.

Authors:  D M Gujral; M Long; J W G Roe; K J Harrington; C M Nutting
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-11-01       Impact factor: 4.126

9.  Definitive radiotherapy for early stage glottic cancer by 6 MV photons.

Authors:  Chi-Chung Tong; Kwok-Hung Au; Roger Kai-Cheong Ngan; Foon-Yiu Cheung; Sin-Ming Chow; Yiu-Tung Fu; Joseph Siu-Kei Au; Stephen Chun-Key Law
Journal:  Head Neck Oncol       Date:  2012-05-18

10.  Risk-adapted partial larynx and/or carotid artery sparing modulated radiation therapy of glottic cancer.

Authors:  Stefan Janssen; Christoph Glanzmann; Gerhard Huber; Gabriela Studer
Journal:  Radiat Oncol       Date:  2014-06-13       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.